Related Experiment Videos
Insights
Treatment for pediatric pelvic rhabdomyosarcoma has evolved. Chemotherapy, with limited surgery and radiation, is now an effective cornerstone, reducing the need for extensive pelvic exenteration in most cases.
Area of Science:
- Pediatric Oncology
- Surgical Oncology
- Medical Oncology
Background:
- Rhabdomyosarcoma is the most common pediatric soft tissue malignancy, frequently involving the pelvis.
- Treatment strategies for pelvic rhabdomyosarcoma remain debated, with varying approaches including pelvic exenteration, radiation, and chemotherapy.
- Paratesticular rhabdomyosarcoma has a more established combined treatment modality.
Purpose of the Study:
- To evaluate and compare treatment regimens for genitourinary rhabdomyosarcoma in children.
- To assess the efficacy of different treatment strategies for pelvic rhabdomyosarcoma, specifically comparing early and later treatment series.
- To determine if chemotherapy can be the cornerstone of treatment, minimizing extensive surgical interventions.
Main Methods:
- Retrospective analysis of 19 children diagnosed with rhabdomyosarcoma, including 17 with pelvic and 2 with paratesticular disease.
- Division of pelvic rhabdomyosarcoma patients into two series: an early series (pelvic exenteration ± chemotherapy) and a later series (chemotherapy-predominant treatment).
- Evaluation of patient outcomes based on treatment received, including survival rates and disease progression.
Main Results:
- In the early series (n=7), 3 of 7 children survived after pelvic exenteration with or without chemotherapy.
- In the later series (n=10), none underwent pelvic exenteration; 8 of 9 eligible patients survived with chemotherapy or chemotherapy and biopsy, with only one Stage IV death.
- Outcomes suggest improved survival and reduced surgical morbidity with the later, chemotherapy-focused approach.
Conclusions:
- Pelvic rhabdomyosarcoma can be effectively treated with chemotherapy as the cornerstone, supplemented by limited surgery and radiation.
- Extensive pelvic exenteration is now reserved for a select few patients with pelvic rhabdomyosarcoma.
- The shift towards less invasive, chemotherapy-centric treatment has improved outcomes for pediatric pelvic rhabdomyosarcoma.
Abstract:
Rhabdomyosarcoma is the most common soft tissue malignant neoplasm involving the pelvis of children. Debate still exists over whether the best treatment is pelvic exenteration, radiation and chemotherapy or chemotherapy as the cornerstone to treatment, with diminished needs for extensive surgery and prolonged radiotherapy. Contrariwise, there is little debate over the combined treatment modality for paratesticular rhabdomyosarcoma. We have evaluated and treated 19 children with rhabdomyosarcoma, including 17 with pelvic rhabdomyosarcoma and 2 with paratesticular rhabdomyosarcoma. This retrospective study was done to evaluate treatment regimens for patients with genitourinary rhabdomyosarcoma. For patients with pelvic rhabdomyosarcoma the study was divided into 2 series. In an early series 6 of 7 children had a pelvic exenteration with or without chemotherapy. Of these 7 children 3 are well 15 to 27 years following diagnosis. In a later series of 10 children, when chemotherapy was used more commonly, none underwent pelvic exenteration. Of these 10 patients 7 had chemotherapy or chemotherapy and biopsy only. Only 1 child, who presented with stage IV disease, died in this series. Another child with stage III disease had progressive disease despite chemotherapy and subsequent cystoprostatectomy. Thus, of 9 remaining patients 8 are well from 1 to 8 years. It appears that pelvic rhabdomyosarcoma can be treated effectively with chemotherapy, and limited surgery and radiation. Fortunately, pelvic exenteration can now be limited to a select few.